Welcome to our dedicated page for TruBridge SEC filings (Ticker: TBRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TruBridge, Inc. (NASDAQ: TBRG) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, drawn in real time from the EDGAR system and supported by AI-powered analysis. TruBridge is a healthcare technology and solutions company focused on rural and community hospitals and providers, and its filings offer detailed insight into how it reports financial performance, manages risk, and governs its operations.
Key documents for TruBridge include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company presents audited and interim financial statements, segment information for its Financial Health and Patient Care business units, and discussions of risk factors and internal control over financial reporting. For example, TruBridge has disclosed material weaknesses related to revenue processes and customer contract changes in prior years, and it has reported on changes to its independent registered public accounting firm, including the dismissal of Grant Thornton LLP and engagement of KPMG LLP.
Current reports on Form 8-K capture material events such as quarterly earnings releases, leadership changes, board refreshment actions, cooperation agreements with major shareholders, and financing developments like the 2025 Amended and Restated Credit Agreement with its lending partners. These filings help investors understand how TruBridge is addressing governance, capital structure, and strategic priorities in the context of rural and community healthcare.
On this page, users can review TruBridge’s Forms 10-K and 10-Q, 8-Ks describing significant corporate events, and other exhibits referenced in those reports. AI-generated summaries highlight the main points of each filing, explain complex accounting or control matters in plain language, and surface items related to revenue cycle management, EHR and patient engagement operations, internal control conclusions, and auditor changes. Filings related to executive and director arrangements, such as severance agreements and board appointments, are also accessible, along with any associated exhibits.
By using these tools, readers can quickly understand what TruBridge reports to regulators about its financial health, operational segments, governance, and risk profile, without having to parse every line of the underlying documents themselves.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of 744,705 TruBridge Inc common shares, representing 4.96% of the class as of December 31, 2025.
Vanguard reports no sole voting or dispositive power, only shared authority, and states the position is held in the ordinary course of business without any intent to change or influence control of TruBridge. The filing also notes an internal realignment at Vanguard under which certain subsidiaries are expected to report beneficial ownership separately while continuing the same investment strategies.
TruBridge, Inc. received a Schedule 13G reporting that investment entities Camac Partners, Camac Capital, Camac Fund and individual investor Eric Shahinian beneficially own 861,638 shares of TruBridge common stock, representing 5.7% of the company. The group reports shared power to vote and dispose of all these shares. The 5.7% figure is based on 15,008,986 TruBridge shares outstanding as of November 4, 2025. The filers state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of TruBridge.
TruBridge, Inc. director Damien Leonard filed an initial ownership report showing how his interests in the company’s common stock are held. As of January 12, 2026, the filing lists 0 shares of common stock held directly in his own name. It also reports 2,130,000 shares of common stock held indirectly through L6 Holdings Inc. and 850,000 shares held indirectly through Pinetree Capital Ltd.
The disclosure explains that the L6 shares are owned directly by L6 Holdings Inc., where Leonard is a Managing Director, and the Pinetree shares are held through an affiliated partnership structure under Pinetree Capital Ltd., where he is President. Leonard disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, meaning he is not conceding full personal ownership for regulatory purposes.
TruBridge, Inc. reported that institutional investor BlackRock, Inc. filed an amended ownership statement showing it beneficially owns 746,291 shares of TruBridge common stock, representing 4.97% of the outstanding class as of 12/31/2025.
BlackRock reports sole voting power over 738,004 shares and sole dispositive power over 746,291 shares, with no shared voting or dispositive power. The stake is held in the ordinary course of business and is described as a passive investment, not for the purpose of changing or influencing control of TruBridge. Various underlying clients have rights to dividends or sale proceeds, but no single client has more than 5% of the total outstanding common shares.
TruBridge, Inc. and investors L6 Holdings Inc. and Pinetree Capital Ltd. entered a cooperation agreement that reshapes the company’s board and formalizes how these investors will act. L6 Holdings reports beneficial ownership of 2,130,000 TruBridge common shares, or 14.2% of the class, while Pinetree reports 850,000 shares, or 5.7%.
The board will be expanded from nine to ten directors and Damien Leonard will be appointed as a new director and nominated for election at the 2026 annual meeting, with an expected role on the Compensation Committee. Several long-tenured directors are expected to retire after the 2026 and 2027 annual meetings, and the board size is to be kept at no more than seven directors from the 2026 meeting through the cooperation agreement’s termination. In return, the reporting persons agree to voting commitments aligned with board recommendations in most cases, customary standstill and non‑disparagement provisions, and a cap on acquiring more than 20% of TruBridge’s outstanding common stock.
TruBridge, Inc. entered into a cooperation agreement with Pinetree Capital Ltd. and L6 Holdings Inc., under which the company will expand its board by one seat and appoint Damien Leonard as a director, effective January 12, 2026, and nominate him at the 2026 annual meeting. The company confirmed that director David A. Dye will not stand for reelection at that meeting, and two additional long‑serving directors will retire at the 2026 annual meeting, with another long‑serving director retiring at the 2027 annual meeting. After the 2026 annual meeting, the board will be capped at seven directors without Pinetree’s consent, and the board will give due and serious consideration to a Pinetree‑recommended candidate in connection with the 2027 transition.
During the term of the agreement, Pinetree will generally vote its TruBridge shares in line with the board’s recommendations, subject to specified exceptions, and is subject to standstill and non‑disparagement provisions, including a cap on beneficial ownership at 20% of outstanding common stock. Mr. Leonard is expected to join the compensation committee, has waived his director fees, and there are no disclosable related‑party transactions or family relationships tied to his appointment.
TruBridge, Inc. (TBRG)$20.42 on 11/17/2025, 3,639 shares at
TruBridge, Inc. (TBRG) reported insider share purchases by group filers including L6 Holdings Inc. and Pinetree Capital Ltd. Acting through Pinetree Investment Partnership, they bought 20,707 common shares on 11/17/2025 at a weighted average price of $20.42, 3,639 shares on 11/18/2025 at $20.84, and 8,501 shares on 11/19/2025 at $20.70.
After these purchases, one indirect holding line shows 850,000 TruBridge common shares attributed to Pinetree Investment Partnership, while another line shows 1,995,000 shares held indirectly by L6 Holdings Inc. The reporting persons state that prices are weighted averages over multiple trades within the disclosed ranges and that they may be deemed part of a group owning over 10% of TruBridge’s outstanding securities.
TruBridge, Inc. (TBRG) reported insider buying by its Chief Business Officer, who filed a Form 4 as a single reporting person. The officer purchased common stock in multiple open-market transactions on November 11, 12, 13, 14 and 17, 2025.
The reported weighted average purchase prices were $19.39, $19.95, $20.16, $20.15 and $20.46 per share, each based on multiple trades within stated intraday price ranges. Following these transactions, the officer directly beneficially owned 57,492 shares of TruBridge common stock.
TruBridge, Inc. reported Q3 2025 results, showing steady revenue and a swing to profitability. Total revenue was $86,106 thousand versus $84,700 thousand a year ago, with segment revenue of $54,501 thousand from Financial Health and $31,605 thousand from Patient Care. Operating income rose to $4,068 thousand from $2,814 thousand. Net income was $5,602 thousand compared with a net loss of $9,148 thousand in Q3 2024, or $0.37 per diluted share.
For the nine months, revenue reached $259,043 thousand versus $254,416 thousand, and net income was $8,641 thousand versus a net loss of $15,390 thousand. Interest expense declined year over year, and the company recorded an income tax benefit influenced by the July 2025 OBBBA legislation allowing deductibility of domestic R&D. Cash from operations was $28,107 thousand year-to-date, ending cash was $19,920 thousand, and total debt obligations were $165,166 thousand, with long‑term debt of $161,363 thousand. Deferred revenue ended at $8,197 thousand. As of November 4, 2025, shares outstanding were 15,008,986.